ANDHealth+
ANDHealth+ Program
ANDHealth+ is Australia’s only dedicated incubator
for digital health companies. Places in ANDHealth+
are highly competitive and companies receive up to
9 months of intensive coaching, support and project funding, whilst being guided by a multi-sectoral C-suite advisory panel.
Program Overview
ANDHealth+ supports a select cohort of evidence-based digital health companies to make substantial progress towards successfully raising institutional investment and commercialising internationally. Applicants are assessed by more than a dozen C-suite judges from our corporate members representing a diverse background of industries, ensuring that the perspectives of multiple stakeholders in digital health are represented. Our members represent companies from across the pharmaceuticals, medical devices, health software and design, health IT, health data analytics and benchmarking, universities, medical research institutes, clinical sites and professional services.

Specifically, all members of our selection panel have had direct involvement in:

• Product development of a market-ready product which is evidence-based and has a sustainable business model;

• Development and implementation of digital health technologies within a real world setting;

• Negotiation of a significant (preferably international) commercial agreement between two or more parties, where at least one party is from industry; and/or

• Raising a significant amount of capital for one or more digital health companies.
Program Benefits
Cohort companies work with a panel of expert mentors including a subset of the judging panel for 6-9 months, meeting regularly, to create a bespoke project plan. The project plan’s objectives are informed by a multidisciplinary due diligence processes, which identifies specific elements of the cohort company’s business strategy which would deter enterprise customers or professional investors. The resulting impact is highly tailored to each company and involves no formal curriculum. Other unique features of ANDHealth+ INCUBATE are:

✓ No equity: As a non-profit initiative, ANDHealth does not require any transfer of equity from program participants. This also allows ANDHealth to provide advice which is free of the conflicts of interest which arise in many company accelerator and incubator models.

✓ No intellectual property transfer:
ANDHealth does not assume any ownership or require any royalties from intellectual property in the project.

Each project will be supported by up to $60,000* to fund specialist third-party services and activities to deliver on the mutually agreed project outcomes.

Each company receives Over $250,000 of in-kind support from ANDHealth members and partners.

✓ Hands-on support and advice specific to your project
from ANDHealth’s commercial members and international expert network. This gives participants access to their own advisory board comprised of professionals with a proven track record in digital health product development and commercialisation.

Facilitated introductions to national and international networks of investors, global healthcare and technology companies and specialised service providers.

Cohort and Alumni only events, access to international experts, involvement in ANDHealth policy initiatives and promotion across the Australian healthcare landscape.


ANDHealth+ Alumni
ANDHealth is extremely proud of the success experienced by our graduating cohort companies of FY2018 and FY2019. Their growth is indicative of the enormous untapped economic and healthcare impact potential of our nascent digital health sector.
Cohort Company Outcomes (as at March 2021):
$42.7M
Raised (dilutive & non-dilutive)
$26.7M
New Revenue
249
New jobs (FTEs)
16
New CxO Roles
874
Commercial pilots commenced
44
Clinical trials and studies commenced
21
New international
market launches
203
New commercial customers
176,400
New patients served
375
New operational sites
57
New partnerships formed
143
New product releases
Eligible projects should focus on the development of clinical and/or commercial evidence to significantly improve the project’s ability to raise growth capital and/ or execute on a market entry or growth strategy.

• Technology Solutions must fall within the definition of digital health as outlined in FDA definition of digital health and project timelines should be approximately 6 months or less.
• Technologies should have achieved proof of concept/proof of principle and must be evidence-based with a clear focus on changing outcomes for patients.
• Some customer traction or pilot activity should have been undertaken or be in progress.

Applicants must:
• have at least one full-time executive (preference will be given to applicants with a full-time core team in place);
• have the ability to resource the applicant’s contributions to the project plan (operational runway, time, resources, headcount);
• have a working prototype or ideally a product which is well progressed; and
• be a registered company and must be able to demonstrate that they are authorised to use any IP required to perform the project

Preference will be given to companies which have completed the ANDHealth Masterclass ACCELERATE Program prior to applying and/ or applicants which can demonstrate significant understanding of the complexity of the challenges of digital health.

Ineligible activities: ANDHealth does not provide financial support directly to the company or support non-project related expenses such as staff or contractor costs, software or hardware development, marketing, fees for a customer to use/purchase your product or service, ‘business as usual’ or the time commitment of applicant’s staff to the project.
Can I talk to someone about the program and my application
Yes. 30 minute meetings with the ANDHealth Program team can be scheduled here and via the ANDHealth website
Who is on the selection panel?
The selection panel is drawn from ANDHealth’s key partners and corporate members which includes representatives from the following companies: Novartis Pharmaceuticals, Planet Innovation, RMIT, Curve Tomorrow, Murdoch Children’s Research Institute, Potential X, AusBiotech and HealthXl.
When do I find out if I am shortlisted or successful?
To be advised
Do you fund clinical trials?
Where a trial is clearly focused on securing the clinical and/or commercial evidence to support the raising of growth capital and progress the market entry strategy it would be considered however early stage clinical work would not be considered.  You must have sufficient data to support the claims of your working prototype.
What happens to the information I submit?
All information submitted will be treated as commercial in confidence and will be circulated to the ANDHealth Selection panel and ANDHealth team only for assessment purposes. All members of the Selection Panel fall under enterprise wide confidentiality agreements via the ANDHealth Corporate Member Agreement. If you wish to review our Privacy Policy please click here.
Projects will be workshopped and determined with successful applicants as part of the program initiation.

Types of proposed projects might include:
• Product verification and validation
• Clinical evidence and outcomes
     ○  Efficacy in a clinical or industry setting and voice of users
• Commercial strategy, evidence and outcomes
     ○  Voice of Paying Customer Studies
     ○  Business and revenue model definition and refinement
     ○  Health economics and business validation in the health setting
     ○  Regulatory certification or roadmap to certification (eg, TGA, FDA)
     ○  Reimbursement and pricing strategy
     ○  International market entry

Examples of previously funded projects:
• International market entry strategy including mapping of reimbursement and procurement pathways
• Health economics assessments
• Clinical trial protocol review and refinement
• Regulatory strategies for major markets
• Direct costs of a pivotal pilot study
• Third party expert validation of product
• Independent valuation assessments
• ANDHealth+ INCUBATE Applications are currently not open. Please click here to subscribe to updates and be notified when the program is open in 2021.

• Applications must be lodged through the online platform accessible via the ANDHealth website

• All applicants must articulate a project for which participation in the program will improve the likelihood of securing investment and/ or substantially progress market entry.

• Applications are initially assessed by ANDHealth and the Selection Panel on a rolling basis. ANDHealth+ attracts a significant number of highly detailed applications and applicants should expect to wait 4-8 weeks for a response.

• Shortlisted applicants will be required to present to members of the Selection Panel. Presentations will be 30 minutes and allow a further 30-45 minutes for questions.

• Successful applicants will be required to work with their advisory group to prepare a comprehensive project plan and supporting budget which will form the basis of a project agreement with ANDHealth and any third-party suppliers as necessary.
The following topics will be considered by the selection panel during the assessment and shortlisting process:

• Extent to which the product delivers value through improved diagnosis, prevention, treatment and/or management of chronic and acute conditions for the benefit of the patient.

• Demonstrated understanding of the end user and how they will interact with the product, including voice of customer, evidence of clinical market appetite, competitive position and product advantage.

• Maturity of the technology, including level of product evidence including clinical trials and technical certification, consideration of regulatory certification strategy, and use of the product in a clinical or market setting.

• Market/investment/business case, including value proposition, size of market and pathway to market, intellectual property strategy and position, barriers to market entry and business model.

• Team, including business skills, technical skills, ability to achieve market uptake.

• Extent to which the proposed project will positively affect clinical and commercial readiness of the project.
Testimonials
Digital health companies require specialist support to commercialise. The type of support ANDHealth provides is vital to the early stages of digital health companies to allow them to accelerate their growth. Personify Care is growing rapidly, headquartered in SA, exporting internationally, currently hiring 3 new full-time roles and will expand our team further this financial year; we need to support emerging digital health companies to expand this sector and create digital health jobs from companies headquartered in SA.
Ken Saman
CEO Personify Care
Digital health is an emerging and exponentially growing sector of the health ecosystem. As such, clinicians and entrepreneurs require specialised support to navigate uncharted waters of regulation and evidence-based medicine. It is essential to the growth of the digital health sector in South Australia that we provide this specific support to digital health companies here. I have observed ANDHealth's operations in other states over the last few years and applaud their commitment and the quality of the expertise that they put around the digital health companies that they support. This is resulting in not only health innovation but strong commercial outcomes from the companies they have supported.
Peter Bradley
VP Global Business Development, LBT Innovations
I am very supportive of the work ANDHealth is doing which is unique in the health sector in Australia. Their programs provide invaluable support and advice to people looking to develop, invest and grow in the healthcare IT industry through offering access to business and commercialisation support, deep knowledge of the sector and much needed support to new entrants. I would have welcomed access to these skills as we developed from early stage to full commercialisation.
Kate Quirke
Chief Executive Officer and Managing Director, Alcidion Group Limited (ASX:ALC)
From my perspective as an Advisor to numerous Digital Health organizations, ANDHealth really stands out as a visionary organization with unique leadership that understands the need to target real problems in healthcare and address them with innovation and transformation that are grounded in economic sustainability and successful long-term outcomes.
Aenor J. Sawyer, MD
Chief Medical Officer, NASA, Translational Research Institute for Space Health
“ANDHealth is a key regional organisation for digital health companies in the Australiasia region. Through our involvement with ANDHealth we have made key a range of key international and local connections. We have networked with, shared, and learnt from the ANDHealth community in a collaborative and progressive environment.”
Garth Sutherland
Founder, Adherium Limited
In a relatively short period of time, ANDHealth has made a positive impact and delivered measurable benefits to the digital health and broader biotechnology sectors.
Dr Chris Nave
Managing Director, Brandon Capital Partners
I think the organisation’s proactive attitude, collaborative nature, strategic connections, and expertise are highly beneficial to the growing digital health community; and am delighted to be able to add my name to the list of those supporting ANDHealth’s activities in the future to build expertise in digital health commercialisation with a view to contributing to the nation’s economic prosperity.
Anton van den Hengel
Director, Australian Institute for Machine Learning, School of Computer Science, University of Adelaide
Australia’s digital health sector will experience significant growth over the coming decades. ANDHealth has played and will continue to play a vital role in the development and growth of this sector in Australia, which will be a significant opportunity for STEM job creation and economic growth in the country. I would love to continue supporting ANDHealth in anyway that I can to promote the sector in Australia.
Jarred Shein
Head of Business Development, Asia Pacific, Qure Ventures
We acknowledge the positive impact that ANDHealth has had on the sector and look favourably on their pursuit of public and private funding to support future operations. I believe ANDHealth has delivered great value to the sector and we believe the dedication solely to digital health and informed by industry leaders with proven backgrounds and the national and international networking opportunities in digital health commercialisation through members, partners and networks are of particularly great value.
Dr Rob Grenfell
Director, CSIRO Health and Biosecurity

Join our
mailing list

Stay up to date on news, programs and events
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.